Vincent Medical Holdings Limited (1612) AI Stock Analysis

• Market Cap: HK$623.49M
• Dividend Yield: 4.32%
• Average Volume (3M): 3.96M
• Price to Earnings (P/E): 7.0
• Beta (1Y): 0.52
• Revenue Growth: 17.93%
• EPS Growth: 36.82%
• Country: HK
• Employees: 1,328
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.08
• Shares Outstanding: 656,300,350
• 10 Day Avg. Volume: 1,774,600
• 30 Day Avg. Volume: 3,961,733
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.50
• Price Target Upside: 57.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: HK$1.50 ▲(57.89% Upside)

Vincent Medical Holdings Limited receives a strong overall score due to its robust valuation metrics and positive technical indicators. The company's financial performance is solid, with room for improvement in cash flow management. The absence of earnings call data and corporate events does not detract from the overall positive outlook.

Vincent Medical Holdings Limited Business Overview & Revenue Model

Company Description

Vincent Medical Holdings Limited, an investment holding company, researches, develops, manufactures, markets, and sells medical devices. It operates in two segments, Original Equipment Manufacturing (OEM) and Original Brand Manufacturing. The company develops medical devices focusing on respiratory products; imaging contrast media power injector disposables; and orthopedic and rehabilitation products for OEM customers. Its respiratory products portfolio includes humidification systems, nCPAP interface systems, respiratory care units, electronic air-oxygen blenders, and anesthesia systems. The company's orthopedic and rehabilitation products comprise various adjustable rehabilitation braces for support and protection, and rehabilitation of various skeletomuscular parts after injury or surgery. It also develops robotic hand training devices. Vincent Medical Holdings Limited sells its products under the Inspired Medical, Hand of Hope, and Hypnus brand names in the People's Republic of China, the United States, the Netherlands, Australia, Japan, and internationally. The company was founded in 1997 and is headquartered in Hung Hom, Hong Kong. Vincent Medical Holdings Limited is a subsidiary of Vincent Raya International Limited.

How the Company Makes Money

Vincent Medical Holdings Limited generates revenue through the sale of its medical devices and equipment. The company's key revenue streams include product sales in respiratory care, anesthesia, and orthopedic rehabilitation. Vincent Medical Holdings Limited collaborates with various healthcare institutions and distributors to expand its market reach and enhance its product offerings. Additionally, the company invests in research and development to innovate and maintain a competitive edge in the medical device industry. Strategic partnerships and a focus on quality and compliance with international standards also contribute to the company's earnings.

Vincent Medical Holdings Limited Financial Statement Overview

Summary

Vincent Medical Holdings Limited shows strong revenue growth and solid equity positioning, reflective of its potential in the medical devices industry. However, cash flow management and income volatility remain areas for improvement. Despite these challenges, the company's low leverage and improving profitability metrics suggest a stable financial foundation with room for growth.

Income Statement

Vincent Medical Holdings Limited demonstrated a positive revenue growth rate of approximately 11.56% for 2024 compared to 2023. The gross profit margin for 2024 was approximately 32.48%, indicating healthy profitability, although the net profit margin was lower at about 8.64%. The EBIT margin was approximately 9.95%, and the EBITDA margin was 12.49%, showing reasonable operational efficiency. However, past fluctuations in EBIT and net income suggest some volatility.

Balance Sheet

The company maintains a solid equity base with an equity ratio of approximately 62.93% in 2024. The debt-to-equity ratio is relatively low at about 0.17, suggesting a conservative leverage approach. Return on equity improved to approximately 11.95% in 2024, indicating good returns on shareholder investment, although past years showed significant swings.

Cash Flow

The company's free cash flow was positive in 2023 but declined to zero in 2024, indicating potential challenges in cash generation. The operating cash flow to net income ratio was zero in 2024, highlighting a need for improvement in converting income to cash. Historical free cash flow growth was volatile, reflecting the need for better cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	800.96M	717.97M	629.24M	777.72M	1.16B
Gross Profit	259.99M	222.59M	147.83M	243.83M	478.79M
EBITDA	100.00M	104.43M	28.29M	119.52M	334.17M
Net Income	69.17M	57.27M	-17.40M	60.70M	216.87M
Balance Sheet
Total Assets	919.68M	786.61M	726.70M	846.15M	946.87M
Cash, Cash Equivalents and Short-Term Investments	173.44M	175.78M	159.34M	173.17M	169.07M
Total Debt	99.65M	37.38M	60.39M	62.96M	84.69M
Total Liabilities	336.33M	243.52M	228.09M	245.72M	341.69M
Stockholders Equity	578.55M	541.84M	498.01M	598.36M	611.56M
Cash Flow
Free Cash Flow	-26.52M	61.28M	57.67M	94.48M	142.19M
Operating Cash Flow	73.48M	124.97M	76.27M	119.43M	204.77M
Investing Cash Flow	-98.81M	-62.37M	-18.61M	-20.69M	-132.19M
Financing Cash Flow	26.39M	-45.37M	-67.84M	-101.16M	10.13M

Vincent Medical Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1612, the sentiment is Positive. The current price of 0.95 is below the 20-day moving average (MA) of 1.03, above the 50-day MA of 0.95, and above the 200-day MA of 0.54, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.36 is Neutral, neither overbought nor oversold. The STOCH value of 10.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1612.

Vincent Medical Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1612	74 Outperform	HK$623.49M	6.99	14.73%	4.32%	17.93%	36.82%
2216	57 Neutral	HK$1.48B	-11.51	-9.03%	―	-30.60%	28.61%
6118	52 Neutral	HK$527.96M	13.92	2.03%	―	-2.77%	―
2500	50 Neutral	HK$1.42B	-2.02	-32.31%	―	-8.56%	-14.84%
2170	47 Neutral	HK$836.99M	-3.25	-20.74%	―	11.43%	4.88%
2393	41 Neutral	HK$298.19M	-1.70	199.66%	―	6.10%	-115.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Vincent Medical Holdings Limited Corporate Events

Vincent Medical Holdings Achieves Record Interim Results with 18.1% Revenue Growth

Vincent Medical Holdings Limited reported its strongest interim results in four years for the six months ending June 30, 2025, with an 18.1% increase in revenue to HK$449.4 million and a 55.1% rise in profit attributable to owners, reaching HK$51.6 million. The impressive performance was mainly driven by a 28.6% surge in revenue from the imaging disposable products segment, alongside resumed growth in the respiratory products segment, which compensated for the decline in the orthopaedic and rehabilitation segment. The company’s gross profit increased by 33.4% due to economies of scale and improved operating efficiency, resulting in a gross profit margin improvement from 31.3% to 35.4%. The board declared an interim dividend of HK2.4 cents per share, reflecting the company’s robust financial health and commitment to its dividend policy.

The most recent analyst rating on (HK:1612) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.

Vincent Medical Holdings Announces Interim Dividend for 2025

Vincent Medical Holdings Limited has announced an interim dividend of HKD 0.024 per share for the six months ended 30 June 2025, with the payment date set for 26 September 2025. This announcement reflects the company’s financial health and commitment to returning value to its shareholders, potentially strengthening its position in the medical industry.

The most recent analyst rating on (HK:1612) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.

Vincent Medical Enhances Governance with New Nomination Committee Appointments

Vincent Medical Holdings Limited has appointed Dr. Leung Ming Chu and Mr. Au Yu Chiu Steven to its Nomination Committee, effective August 20, 2025. This decision aligns with new corporate governance requirements and aims to enhance the diversity and governance practices of the company, potentially impacting its operational standards and stakeholder confidence.

The most recent analyst rating on (HK:1612) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.

Vincent Medical Holdings Announces Board Composition and Roles

Vincent Medical Holdings Limited has announced the composition of its board of directors and their respective roles within the organization. The board includes a mix of executive, non-executive, and independent non-executive directors, with specific members assigned to various committees such as Audit, Nomination, Remuneration, Risk Management, and Environmental, Social, and Governance. This announcement reflects the company’s commitment to structured governance and strategic oversight, which could enhance its operational efficiency and stakeholder confidence.

The most recent analyst rating on (HK:1612) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.

Vincent Medical Holdings Updates Audit Committee Terms to Enhance Governance

Vincent Medical Holdings Limited has announced amendments to the terms of reference for its Audit Committee, effective August 20, 2025. The committee is tasked with overseeing the company’s financial reporting, risk management, and internal control systems, as well as ensuring the integrity of financial statements and the independence of external auditors. These changes aim to enhance the company’s governance structure and ensure effective communication among directors and auditors, potentially strengthening its market position and stakeholder confidence.

The most recent analyst rating on (HK:1612) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.

Vincent Medical Holdings Updates Nomination Committee Terms

Vincent Medical Holdings Limited has announced amendments to the terms of reference for its Nomination Committee, effective from August 20, 2025. The Committee is tasked with identifying and recommending candidates for the Board of Directors, evaluating board performance, and developing nomination guidelines. The Committee must consist of at least three members, with a majority being independent non-executive directors, and include at least one member of a different gender. This move is likely to enhance the company’s governance structure and ensure diversity in its leadership.

The most recent analyst rating on (HK:1612) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.

Vincent Medical Updates Remuneration Committee Terms

Vincent Medical Holdings Limited has announced amendments to the terms of reference for its Remuneration Committee, effective from August 20, 2025. The changes emphasize the committee’s role in determining remuneration policies for directors and senior management, ensuring a majority of independent non-executive directors, and maintaining a minimum of three members. This move is likely aimed at enhancing governance and aligning the company’s remuneration practices with industry standards, potentially impacting stakeholder confidence positively.

The most recent analyst rating on (HK:1612) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.

Vincent Medical Holdings to Discuss Interim Results and Dividend

Vincent Medical Holdings Limited has announced a board meeting scheduled for August 20, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. This meeting will also consider the publication of these results and the potential payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

Vincent Medical Holdings Announces Significant Profit Increase for H1 2025

Vincent Medical Holdings Limited has issued a positive profit alert, indicating an expected unaudited consolidated profit of at least HK$50.0 million for the first half of 2025, marking a significant increase of over 50% compared to the same period in 2024. This growth is attributed to increased sales orders in the imaging disposable products segment and improved gross profit margins due to economies of scale and operational efficiency. The final unaudited interim results are still being finalized, and stakeholders are advised to exercise caution when dealing with the company’s shares.